Full access
Professional News
Published Online: 16 July 2004

Psychiatry Not Alone in Concern

Publication: Psychiatric News
Volume 39, Number 14
https://doi.org/10.1176/pn.39.14.0390044
Track CitationsAdd to favorites
The controversy over the pediatric use of antidepressants is just one example of concerns over the validity of the data from randomized controlled trials (RCTs) that medicine uses as its evidence base. The concern occurs throughout medicine.
A major source of state-of-the-art treatment data is the new research findings unveiled at medical meetings. These meetings present thousands of abstracts each year, many with data from the nearly 50,000 RCTs conducted in the U.S. annually.
But after the meeting, what happens to all that preliminary data? A mid-1990s study of research presented at an emergency medicine meeting found that of 223 unpublished abstracts, only 20 percent were published in peer-reviewed journals within the following three years.
A review last year found that of 510 abstracts of large, phase 3 RCTs presented at meetings of a major oncology group between 1989 and 1998, 81 percent were published within five years of the meeting at which they were presented; the remainder were not published within five years. Industry-funded RCTs with a positive outcome were significantly more likely to be published.
Another review this year again found that funding and outcome are significantly related to publication. Of 332 RCTs (158 on drugs, 87 on surgical treatments, 87 on “other therapies”) 37 percent acknowledged industry funding. Overall, those that were funded by industry were 1.9 times more likely to be positive toward the treatment studied. Surgical trials were eight times more likely to be positive, and drug trials were five times more likely to have pro-industry results.
Though psychiatry was at the forefront of the call for a clinical trials registry to help track RCT data, response has been broadly supportive from the AMA, National Institutes of Health, Food and Drug Administration, and Pharmaceutical Research and Manufacturers of America (the industry's main lobbying group). All seemingly agree that it's time to change the current system.

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 39 • Number 14 • July 16, 2004
Pages: 44

History

Published online: 16 July 2004
Published in print: July 16, 2004

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.